BioPharma Dive July 29, 2024
The German pharmaceutical company is acquiring San Diego-based Nerio and its checkpoint inhibitor research for up to $1.3 billion.
Boehringer Ingelheim is investing again in immuno-oncology, announcing Monday a deal to acquire the San Diego-based biotechnology startup Nerio Therapeutics and its slate of preclinical drug candidates.
Worth up to $1.3 billion, the acquisition hands Boehringer access to a research program the German pharmaceutical company envisions as a “potential key centerpiece” of its immuno-oncology drug portfolio. Nerio’s small molecule drugs are designed to block enzymes known as PTPN1 and PTPN2 that brake the body’s immune response to tumors.
Targeting such “immune checkpoints” has animated much of cancer research and development over the past decade, with mixed results. Checkpoint inhibitors aimed at...
Today's Sponsors
Today's Sponsor